Highlights from: 27th Congress of the European Society for Medical Oncology

Clinical Colorectal Cancer

Volumn 2, Issue 3, 2002, Pages 140-145

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; PRODRUG;

ADVANCED CANCER; ANEMIA; BOLUS INJECTION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MEDICAL SOCIETY; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0036865425     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70319-X     Document Type: Conference Paper

References (25)

1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10:896-903.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
3. Rothenberg M, Meropol N, Poplin E, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801-3807.
4. Laadem A, Cvitkovic E. Oxaliplatin: a first DACH-platinum in oncology. Bull Cancer 2001; 88:S9-S13.
5. Fischel JL, Etienne MC, Formento P, et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4:2529-2535.
6. Plasencia C, Taron M, Abad A, et al. Synergism of oxaliplatin (OXA) with either 5-fluorouracil (5FU) or topoisomerase I inhibitor in sensitive and 5-FU resistant colorectal cell lines is independent of DNA-mismatch repair and p53 status. Proc Am Soc Clin Oncol 2000; 19:204a (Abstract #793).
7. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
9. Goldberg R, Morton R, Sargent D, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup Study. Proc Am Soc Clin Oncol 2002; 21:128a (Abstract #511).
10. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in Metastatic Colorectal Cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (Abstract #494).
11. Comella P, Massidda B, Filipelli G, et al. Oxaliplatin plus folinic acid/fluorouracil i.v. bolus (OXAFAFU) versus irionotecan plus folinic acid/fluorouracil i.v. bolus (IRIFAFU) as first-line treatment of advanced colorectal carcinoma (ACC): Southern Italy Cooperative Oncology Group Trial 0103. Ann Oncol 2002; 13:78 (Abstract #282P).
12. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
13. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patient with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
14. Twelves C, Butts C, Cassidy J, et al. Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multi-center phase II study. Eur J Cancer 2001; 37 (suppl 6):272 (Abstract #1005).
15. Schleucher N, Tewes M, Achterrath W, et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:141a (Abstract #561).
16. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer (ACRC). Ann Oncol 2002; 13:71.
17. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7:2-8.
18. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
19. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
20. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leuvorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
21. Lutz MP, Schoffski P, Folprecht G, et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24th infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol 2002; 13 (suppl 5):73 (Abstract #265).
22. Anderson N. Iressa, an EGFR inhibitor, shows preclinical promise. Oncology News International 2001; 10.
23. Seymour L, Goss G, Stewart D, et al. A translational research study of ZD1839 at a dose of 750 mg in patients with pre-treated advanced or metastatic colorectal cancer. NCIC CTG IND. 122. Ann Oncol 2002; 13.
24. Goss GD, Hirte H, Lorimer I, et al. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamic (PD) and biological activity study of ZD1839: NCIC CTG Ind.122. Proc Am Soc Clin Oncol 2001; 20:85a (Abstract #335).
25. Hammond LA, Figueroa J, Schwartzberg L, et al. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20:137a (Abstract #544).